Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD30 CAR-T (Huazhong University of Science and Technology)
- Development stage
- Unknown
- Lead developer
- Huazhong University of Science and Technology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
This is an investigational third-generation chimeric antigen receptor (CAR) T-cell therapy targeting the CD30 antigen. Developed by researchers at Tongji Hospital, Huazhong University of Science and Technology, the therapy involves genetically modifying a patient's autologous T cells to express a CAR that recognizes and eliminates CD30-positive malignant cells. It is primarily being evaluated for the treatment of relapsed or refractory CD30-positive lymphomas, such as classical Hodgkin lymphoma and anaplastic large cell lymphoma. Clinical studies have explored its use both as a monotherapy and in combination with the PD-1 inhibitor camrelizumab to enhance anti-tumor activity. Manufacturing support for the product is provided by Wuhan Bio-Raid Biotechnology.
- Other names
- anti-CD30 CAR-Tanti-CD-30 CAR-Tanti-CD 30 CAR-TCD30-directed CAR-T cellsCD-30-directed CAR-T cellsCD 30-directed CAR-T cells
02
Targets
CD30 (CD30 antigen)
Beyond the preview
Go deeper on CD30 CAR-T (Huazhong University of Science and Technology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD30 CAR-T (Huazhong University of Science and Technology).